eLifeMicrobiologyPeer-reviewed journal article
Heterogeneous efflux pump expression underpins phenotypic resistance to antimicrobial peptides
Ka Kiu LeeiD, Urszula ŁapińskaiD, Giulia TolleiD, Maureen MicalettoiD, Bing ZhangiD, Wanida PhetsangiD, Anthony D. VerderosaiD, Brandon M. InvergoiD, Joseph WestleyiD, Attila BebesiD, Raif YueceliD, Paul A. O’Neill, Audrey FarbosiD, Aaron R. JeffriesiD, Stineke van HouteiD, Pierluigi CaboniiD, Mark A. T. BlaskovichiD, Benjamin E. HousdeniD, Krasimira T. Tsaneva-AtanasovaiD, Stefano PagliaraiD
Abstract
Antimicrobial resistance threatens the viability of modern medical interventions. There is a dire need of developing novel approaches to counter resistance mechanisms employed by starved or slow-growing pathogens that are refractory to conventional antimicrobial therapies. Antimicrobial peptides have been advocated as potential therapeutic solutions due to low levels of genetic resistance observed in bacteria against these compounds. However, here we show that subpopulations of stationary phase Escherichia coli and Pseudomonas aeruginosa survive tachyplesin treatment without genetic mutations. These phenotypic variants display enhanced efflux activity to limit intracellular peptide accumulation. Differential regulation of genes involved in outer membrane vesicle section, membrane modification, and protease activity were also found between phenotypically resistant and susceptible cells. We discovered that formation of these phenotypic variants could be prevented by administering tachyplesin in combination with sertraline, a clinically used antidepressant, suggesting a novel approach for combatting antimicrobial-refractory stationary phase bacteria.
- organism: E. coli
- organism: mouse
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- research focus: cell signaling & trafficking
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 16
- FWCI
- 2.83
- Field percentile
- top 8%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Antimicrobial peptides can generate tolerance by lag and interfere with antimicrobial therapy
D. Sandin Garcia, J. Valle, … M. Torrent Burgas·bioRxiv·Jun 3, 2022
- Bacteria primed by antimicrobial peptides develop tolerance and persist
A. Rodriguez Rojas, D. Y. Baeder, … J. Rolff·bioRxiv·May 19, 2020
- Slow and ad hoc: Unravelling the two features characterizing the development of bacterial resistance to membrane active peptides
A. Majumder, M. K. Prakash·bioRxiv·Apr 19, 2019
- Multiple resistance factors collectively promote inoculum-dependent dynamic survival during antimicrobial peptide exposure in Enterobacter cloacae
A. N. Murtha, M. I. Kazi, … T. Doerr·bioRxiv·Mar 3, 2024
- Speed Matters: Accelerated Pharmacokinetics Reduce Persisters in Escherichia coli
Khairy Mohammed Ali, Ronan A. Murphy, … Jens Rolff·bioRxiv·Apr 25, 2025
- Fast bacterial growth reduces antibiotic accumulation and efficacy
U. Łapinska, M. Voliotis, … S. Pagliara·bioRxiv·Oct 18, 2021